Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

28 October 2025

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC As a significant milestone in its global development progress, this achievement fully validates the drug's substantial clinical potential and market prospects
27 October 2025

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer This marks the fourth Phase III clinical study initiated for JSKN003
24 October 2025

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022 JSKN022 is the Company’s fourth ADC candidate entering clinical development, as well as the world's first PD-L1/αvβ6 bispecific ADC to advance into clinical trials
20 October 2025

Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025 two latest clinical data of primary platinum-refractory OC and HER2-positive mCRC, along with the confirmatory study design of the phase III study in PROC
20 October 2025

Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer This latest designation in colorectal cancer further underscores its clinical value and global development potential across multiple refractory tumor types
18 October 2025

Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session The study demonstrated positive outcomes for both PFS and OS, indicating its potential to change clinical practice guidelines for the treatment of second-line or above GC
16 October 2025

World Breast Cancer Awareness Month | Safeguarding the Flower of Life through Innovation contributing technological strength to global health
12 September 2025

The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration KN026 is the first HER2 bispecific antibody to demonstrate positive results in the second-line treatment of gastric cancer in China.
29 August 2025

Alphamab Oncology Reports 2025 Interim Results and Business Highlights 2025 Interim Results and Business Highlights
04 August 2025

Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE The Company plans to initiate a clinical study of JSKN022 for the treatment of advanced malignant solid tumors